Marrow transplantation and adoptive immunotherapy hematological bone marrow transplantation. Medical search. Frequent questions

He has been working in the field of bone marrow transplantation for hematological malignancies for the last 25 years and is one of the pioneers of the non-myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders. (labiotech.eu)
His main contributions and scientific interests are hematopoietic stem cell transplantation, hematological malignancies, cord blood biology and, transplantation, and adoptive cell-mediated immunotherapy including NK cell biology. (labiotech.eu)
Genetically engineered T cells expressing a chimeric antigen receptor (CAR) are rapidly emerging a promising new treatment for haematological and non-haematological malignancies. (nature.com)
In current clinical development, targeting CD19 + B cell malignancies, which include acute and chronic B-cell leukaemia and B-cell non-Hodgkin lymphomas (NHLs), with anti-CD19 CAR-T cells is one of the most advanced adoptive T-cell therapies and has been approved by the FDA. (nature.com)
T cell immune protection plays a pivotal role in the treatment of patients with hematological malignancies. (hindawi.com)
However, T cell exhaustion might lead to the possibility of immune escape of hematological malignancies. (hindawi.com)
Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
Over the last few decades, the treatment of hematological malignancies has gained tremendous headway, but these diseases still have high morbidity and mortality [ 1 - 3 ]. (hindawi.com)
Traditionally, the treatment of hematological malignancies is administrated by chemotherapy, radiotherapy, and stem cell transplantation. (hindawi.com)
In recent years, with the increased understanding of the molecular genetic basis of these malignancies, immune-targeted therapy has become a new possibility for the treatment of hematological malignancies. (hindawi.com)
It is noted that T cell has great potential for immunotherapy of hematological malignancies. (hindawi.com)
In addition, the isolation and storage of umbilical cord blood hematopoietic stem cells have been used to rebuild the immune system for the treatment of hematological malignancies and might be promising for the dynamic equilibrium expansion of functional T cells [ 12 ]. (hindawi.com)
Investigational cell therapies are addressing a wide range of hematological malignancies. (bdbiosciences.com)
T cells genetically equipped with chimeric antigen receptors (CARs) or TCRs have shown remarkable effectiveness in treating some hematological malignancies, although the efficacy of engineered T cells in treating solid tumors is far from satisfactory. (blogspot.com)
Throughout her research process, T-cell therapies were applied on a broader scale to active patients who had deadly infections after receiving bone marrow transplantation and patients who developed any kind of EBV (Epstein-Barr virus) related malignancies. (blogspot.com)
CAR T cell therapy is a form of engineered adoptive cellular therapy that has shown remarkable efficacy in the treatment of cancer, especially hematologic malignancies. (apbmt.org)
Nevertheless, targeting solid tumors is more challenging than targeting hematological malignancies because of tumor histopathological characteristics, shortage of specific antigens and local strong immunosuppressive microenvironment [ 4 ]. (ijbs.com)
Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study. (ctsicn.org)
The aim of this review is to summarize the PD-1 and PD-L1 biological functions and their alterative expression in hematological malignancies. (biomedcentral.com)
The role of PD-1 and PD-L1 in T-cell immune suppression and the potential for immunotherapy via blocking PD-1 and PD-L1 in hematological malignancies are also reviewed. (biomedcentral.com)
Leukemia, particularly aggressive refractory hematological malignancies unresponsive to upfront therapy, remains a difficult condition to treat. (biomedcentral.com)
Collectively, our results identify how and when to administer TLR agonists to augment T cell-based immunotherapy in the absence or presence of host preconditioning for treatment of advanced malignancies. (biomedcentral.com)

While CAR-T cell therapy has demonstrated a significant clinical effect against malignant blood tumors, TCR-T cell therapies have been tested in hematological and solid tumors. (cip.com.cn)
In the early 80s' donor lymphocyte infusions (DLI) with allo-activated haplo-identical cells from family members were infused in patients affected by hematological diseases or solid tumors. (biomedcentral.com)
Optimization of the design of CAR vectors, exploration of new targets, addition of safe switches and combination with other treatments bring new vitality to the CAR-T cell based immunotherapy against solid tumors. (ijbs.com)

Worldwide, approximately 90,000 first HSCTs-53% autologous and 47% allogeneic-are performed every year, according to the World Wide Network of Blood and Marrow Transplantation. (medscape.com)

Despite their efficiency, adoptive T-cell therapies show unique toxicities, which are distinct from those seen with conventional chemotherapies, monoclonal antibodies (mAbs), and small-molecule-targeted therapies. (nature.com)
Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. (nature.com)
However in the last years, immunotherapies using immune-checkpoint inhibitors (ICI), as well as cellular therapies, have moved into the limelight as promising alternative treatments. (nature.com)
She spent over 13 years researching T-cell therapies to target deadly cancers that occur in patients who have received bone marrow transplants. (blogspot.com)
Among PSCs, the donors available for induced pluripotent stem cells (iPSCs) are greatest, providing a potentially universal cell source for all types of cell therapies including cancer immunotherapies using natural killer (NK cells). (molcells.org)
In the last few years, a renewed interest on adoptive cellular therapies emerged in the field of tumor-immunology due to the remarkable advances in regard to our knowledge of the mechanisms employed by immune system to fight cancer counterbalanced by the pathogenic loops deployed by tumors to escape immune responses. (biomedcentral.com)

This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
The use of allogeneic hematopoietic cell transplantation (HCT) is the most potent immunotherapeutic treatment for hematologic diseases, but its practical use is impeded by acute and chronic graft-versus-host disease (GvHD). (cryostem.org)

Although high-dose chemoradiotherapy used for conditioning prior to autologous bone marrow transplantation (BMT) represent an effective tool for eradication of certain malignant hematological disorders, relapses indicate that the last tumor cell is unlikely to be completely eradicated. (tau.ac.il)
Dr. Nagler established the first public cord blood bank in Israel and performed the first cord blood transplants from related and unrelated donors in genetic and malignant hematological diseases in Israel. (labiotech.eu)
Given the potential importance of MAIT cells in control of microbial infections and protection of epithelial surfaces, we investigated MAIT cell reconstitution in 43 children who underwent hematopoietic stem cell transplantation (HSCT) after myeloablative conditioning for the treatment of malignant hematological disease. (cryostem.org)

In recent years, engineering T cell therapy has made great progress in tumor immunotherapy, which mainly includes T-cell receptor-engineered T cell (TCR-T) therapy and chimeric antigen receptor T cell (CAR-T) therapy. (cip.com.cn)
Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel immunotherapy which modifies T cells with CAR, an artificial fusion protein that incorporates an extracellular antigen recognition domain, a transmembrane domain, and an intracellular domain including costimulation and signaling components [ 4 , 5 ]. (biomedcentral.com)

This atlas is a concise but comprehensive guide to the diverse patterns of response to immunotherapy as observed on Positron Emission Tomography/Computed Tomography (PET/CT) and other conventional imaging modalities, including CT and Magnetic Resonance Imaging (MRI). (nshealth.ca)
TIME possesses distinct populations of myeloid cells and lymphocytes to influence the immune escape of cancer, the response to immunotherapy, and the survival of patients. (biomedcentral.com)
TIME influences the immune escape of cancer, the response to immunotherapy, and the survival rate of patients. (biomedcentral.com)

Hardly a day goes by without hearing of some new cell involved in a new disease treatment: Numerous cellular immunotherapies are currently in clinical development, using natural killer cells, dendritic cells (DCs), macrophages, polyclonal or antigen-specific T cells and lymphokine-activated killer cells. (mastercellbank.com)
The prognosis for leukemia patients who've relapsed or who have residual disease following allogeneic hematopoietic stem cell transplantation is often poor, but we believe that by targeting the minor H antigen, HA-1, through a novel T cell immunotherapy, we can potentially treat and prevent subsequent relapse," said Elizabeth Krakow, M.D., MSc. (elevate.bio)
His main scientific contributions in the last 10 years relate to antigen presentation in dendritic cells and immunotherapy. (euroacadti.eu)

[ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (medscape.com)
Its clinical introduction in 1986 replaced bone marrow (BM) as a stem cell source to almost 100% in the and to autologous approximately 75% in the allogeneic transplant setting. (mastercellbank.com)

allogenic natural killer cells (NK-cells) generated ex vivo from umbilical cord blood progenitor cells in cancer immunotherapy. (mastercellbank.com)

Building off experience in hematopoietic stem cell transplant and exploiting advances in genetic engineering, genome editing, immunology, immunotherapy, stem cell biology, understanding disease mechanisms and cell therapy manufacturing, considerable progress has been made with hundreds of clinical trials underway. (bdbiosciences.com)
OBJECTIVE: This study aims to observe and analyze the clinical characteristics and prognosis of adenovirus (ADV) infection diagnosed by metagenomic next-generation sequencing (mNGS) after haploidentical hematopoietic stem cell transplantation (Haplo-HSCT), which was performed following Beijing Protocol. (bvsalud.org)
METHODS: The clinical data of patients who developed ADV infection diagnosed by mNGS after Haplo-HSCT between January 2019 and March 2021, recorded in three transplantation centers, were retrospectively analyzed. (bvsalud.org)
The clinical application cells began in 1956 with the first successful bone marrow transplant, performed between twins, with bone marrow taken from the healthy identical twin, and given to the other, who had leukaemia. (mastercellbank.com)
This review of cancer immunotherapy brings us to the work of DR. AISHA HASAN - innovative research specialist in clinical pursuit of a cancer immunotherapy breakthrough by harnessing the body's T-cells. (blogspot.com)
Finally, it retrospectively analyze the activation strategies and clinical relevance of existing γδ T cell adoptive immunotherapies. (explorationpub.com)
CAR-T cell therapy has achieved outstanding progresses in clinical observations, which makes it even more attractive in the development of cancer adoptive immunotherapy. (ijbs.com)

Cancer immunotherapy, by relying on this basic recognition method, boosts the anti-tumor efficacy of T cells by unleashing the inhibition of immune checkpoints and expands adaptive immunity by facilitating the adoptive transfer of genetically engineered T cells. (blogspot.com)
Today, a vast number of immunotherapies have been developed- such as monoclonal antibodies (used to block abnormal proteins in a cancer cell), checkpoint inhibitors that remove barriers to anti-tumour immunity, oncolytic virus therapy, cancer vaccines and T-cell therapy. (blogspot.com)
Immunotherapy utilizing T cell immunity has become a new treatment to eliminate cancer cells. (biomedcentral.com)

Hematopoietic Stem Cell Transplantation in Refractory Crohn's Disease: Should It Be Considered? (mdpi.com)

The purpose is to deliver chemotherapy, immunotherapy, and/or radiation to eliminate malignancy, prevent rejection of new stem cells, and create space for the new cells. (medscape.com)

Hematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of hematopoietic stem cells in order to reestablish blood cell production in patients whose bone marrow or immune system is damaged or defective. (medscape.com)
The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
Unlike hematopoietic stem cell transplantation, little is known about the dynamics of immune reconstitution after CAR T cell therapy, including appropriate antimicrobial utilization and immunizations for these patients. (apbmt.org)
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. (cip.com.cn)

We are investigating several approaches for controlling residual tumor cells escaping from chemoradiotherapy by cellular adoptive immunotherapy and amplification of natural defense mechanisms, using recombinant human IL2 (Cetus, Emeryville, CA), in a murine model of leukemia/lymphoma disease (BCL1). (tau.ac.il)
The Sheba Medical Center in Israel has an advanced hemato-oncology center that offers in-house CAR T-cell therapy, the revolutionary immunotherapy that alters a patient's white blood cells to kill cancer cells. (labiotech.eu)
Novel understanding in the interaction between immune system and cancer cells of the patient holds great promise for immunotherapy development [ 4 - 6 ]. (hindawi.com)
The premise of CAR T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. (wikipedia.org)
Cancer immunotherapies aim to support or boost the patient's immune system to enable the effective clearance of cancer cells. (nature.com)
MSCs are multipotent stromal cells that make and restore skeletal tissue and can differentiate into diverse cell types: bone, cartilage, muscle and fat. (mastercellbank.com)
Hematopoietic stem cells (HSCs) used in the treatment of cancers and other immune system disorders are found in the red bone marrow in the central part of most bones but principally in the pelvis, femur, and sternum. (mastercellbank.com)
Cambridge, Mass. - December 6, 2020 - HighPassBio, an ElevateBio portfolio company dedicated to advancing novel targeted T cell immunotherapies, today discussed the ongoing Phase 1 trial of the company's lead product candidate, an engineered T cell receptor (TCR) T cell therapy targeting HA-1 expressing cancer cells in an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting. (elevate.bio)
The abstract for the presentation titled Phase 1 Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for Children and Adults with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT): Trial in Progress, can be found on the ASH website under the abstract number 137726 . (elevate.bio)
Adoptive T cell therapy can be applied to tackling relapse of leukemia post hematopoietic stem cell transplant (HSCT) by targeting the antigens expressed only by the patient's native cells, and not by the cells from the stem cell transplant donor. (elevate.bio)
In the review from Springer Nature), we summarize the development of genetically engineered T cells, outline the most recent studies investigating genetically engineered T cells for cancer immunotherapy, and discuss strategies for improving the performance of these T cells infighting cancers. (blogspot.com)
According to current challenges, there is a need to explore innovative immunotherapies, maximize the tumor-killing efficacy of γδ T cells, and attenuate or eliminate tumor immunosuppression. (explorationpub.com)
There already exist several protocols to genetically modify and differentiate iPSCs into NK cells, and each has its own advantages with regards to immunotherapies. (molcells.org)
In this article, we address structure and signal activation, target selection, affinity optimization, safety modification and gene editing strategies for engineered T cells, and also review the potential synthetic biological approaches and latest progress of engineered T cell therapy in the application of tumor immunotherapy. (cip.com.cn)
Indeed, adoptive cell transfer of allogeneic NK cells have been used for the treatment of leukemia, colorectal cancer, hepatocellular cancer, lymphoma and melanoma. (biomedcentral.com)
Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of transformed monoclonal plasma cells in the bone marrow (BM) [ 1 ]. (biomedcentral.com)
BCMA is not present in other hematological cells like hematopoietic stem cells or other tissues. (biomedcentral.com)
Simpson RJ, Bigley AB, Agha N, Hanley PJ, Bollard CM. Mobilizing Immune Cells With Exercise for Cancer Immunotherapy. (ctsicn.org)
FLT3 ligand regulates thymic precursor cells and hematopoietic stem cells through interactions with CXCR4 and the marrow niche. (ctsicn.org)
instead of targeting tumor cells, the goal of immunotherapy is to augment and expand the immune system's intrinsic antitumor response. (frontiersin.org)
chronic myeloid leukemia (cml) is characterized by increased and unregulated proliferation of granulocytic lineage in the bone marrow and presence of these immature myeloid cells in the peripheral blood with presence of philadelphia (ph) chromosome. (liverpool.ac.uk)
A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets. (jax.org)

An approach known as adoptive T cell therapy, using T cell receptors, or TCRs, can overcome some of the obstacles to establishing an effective immune response to fight off the target tumor. (elevate.bio)
Since researchers identified the molecular evidence of T cell receptors (TCRs) in the 1980's, the recognition of antigens by TCRs has been heavily investigated, and the molecular mechanisms governing this process have been elucidated, laying the foundation for cancer immunotherapy. (blogspot.com)

Elo-KRd treatment did not augment NK cell distribution or activity in blood or bone marrow. (bvsalud.org)

Arnon Nagler is director of the Division of Hematology and the Bone Marrow Transplantation and Cord Blood Bank at the Chaim Sheba Medical Center, Tel-Hashomer, Israel and Professor of Medicine at The Tel Aviv University, Tel-Aviv, Israel . (labiotech.eu)
This, along with the development of unrelated cord blood transplantation and familial haploidentical transplantation methods, have improved the likelihood of finding an appropriate HSCT source in a timely manner. (medscape.com)
Bone marrow was the original and most common source of MSCs and they are also found in Wharton's Jelly, Cord Blood, Adipose Tissue, Molar Teeth, Amniotic Fluid and Peripheral Blood. (mastercellbank.com)

Cytokines, cancer vaccines, adoptive cell transfers, and especially checkpoint inhibitors constitute valuable elements in the immunotherapeutic armamentarium. (frontiersin.org)

Lymphodepletion enhances adoptive T cell transfer (ACT) therapy by activating the innate immune system via microbes released from the radiation-injured gut. (biomedcentral.com)

Dr O'Rourke reviews brain cancer vaccine trials at Penn Medicine, focusing on the EGFRvIII peptide vaccine, offers a synopsis of the application at Penn of adoptive T cell therapy to the brain cancers and considers GBM--surface antigens for CAR therapy in glioma. (pennmedicine.org)
Immunotherapies have revolutionized the treatment paradigms of various types of cancers. (cn1699.cn)
Recently, the Hudecek lab has developed CARs targeting different targets for solid and hematological cancers. (ukw.de)

T lymphocytes for adoptive cell therapy against hematological cancer. (upstate.edu)

Thus, it is imperative to develop more competent and safer immunotherapy approaches by optimizing the design of CAR vectors, exploring new targets, incorporating conditional safe switches and combining with other strategies. (ijbs.com)
The development of strategies by targeting tumor-associated macrophages (TAMs) to stimulate their ability of Programmed Cell Removal (PrCR) provides a promising new immunotherapy for TNBC treatment. (bmj.com)

Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. (ukw.de)

The recent FDA approvals of the programmed cell death protein 1 (PD-1)-targeted checkpoint inhibitors pembrolizumab and nivolumab mark the latest successes in the rapidly expanding field of cancer immunotherapies. (frontiersin.org)

Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. (ctsicn.org)

Using human and mouse TNBC preclinical models, we evaluated the efficacy of PrCR-based immunotherapy by blocking CD47. (bmj.com)

In addition to basic science investigations in such areas as tumor cell invasion, oncogenes, immunotherapy and genetic inheritance, our scientists and physicians participate in national cancer trials. (upstate.edu)

Peripheral blood stem cell transplantations (PBSCT) are now the most common cell therapy procedure. (mastercellbank.com)

Among the different approaches of anti-tumor adoptive cell transfer, allogeneic stem cell transplantation (allo-SCT) represents the first and most consolidated form of immunotherapy on the basis of its graft versus tumor (GvT) effect. (biomedcentral.com)
Hematopoietic Stem Cell Transplantation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (ctsicn.org)
This graph shows the total number of publications written about "Hematopoietic Stem Cell Transplantation" by people in this website by year, and whether "Hematopoietic Stem Cell Transplantation" was a major or minor topic of these publications. (ctsicn.org)
Below are the most recent publications written about "Hematopoietic Stem Cell Transplantation" by people in Profiles. (ctsicn.org)

Anatomy32

Organisms15

Diseases54

Chemicals and Drugs43

Analytical, Diagnostic and Therapeutic Techniques and Equipment82

Psychiatry and Psychology2

Phenomena and Processes35

Anthropology, Education, Sociology and Social Phenomena2

Information Science3

Named Groups3

Health Care12

Malignancies23

Solid tumors3

Blood and Marrow Transplantation1

Therapies6

Hematopoietic cell4

Malignant3

Chimeric antigen receptor2

Response to immunotherapy3

Antigen3

Autologous2

Umbilical cord1

Clinical7

Immunity3

Refractory1

Chemotherapy1

Patients4

Cells22

TCRs2

Augment1

Cord blood3

Cytokines1

Immune system1

Cancers3

Lymphocytes1

Strategies2

Cell Responses1

Inhibitors1

Treatment1

Efficacy1

Genetic1

Peripheral1

Stem cell4